Navigation Links
CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
Date:8/12/2009

ists.

"The introduction of CryoPatch SG represents another step in the broadening applications of the SynerGraft technology to patients and surgeons," said Steven G. Anderson, CryoLife's president and chief executive officer. "CryoPatch SG may offer an attractive tissue reconstruction option for many children born with heart defects."

Management estimates that the U.S. market for CryoPatch SG and other tissues and products for the indications listed above is $15 million. CryoLife anticipates that the first CryoPatch SG will be available for shipment late in the third quarter of 2009.

In February 2008, the Company received a 510(k) clearance from the FDA for its CryoValve((R)) SG pulmonary human heart valve. CryoValve SG is indicated for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures (RVOT), commonly performed in children with congenital heart defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG is then surgically implanted in place of the removed native pulmonary valve.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve((R)) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft((R)) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native or prosthetic pulmonary valves. The Company's BioGlue((R)) Surgical Adhesive is FDA approved as an adjunct to sutures and stapl
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
3. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
4. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
5. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
6. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
7. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
8. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
9. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
10. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
11. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... unique, Rice University-based program that combines a traditional ... undergraduate research internship in nanotechnology, has been awarded ... Heiskell Award for Innovation in International Education. , ... and honor the most outstanding initiatives in international ...
... January 28 Nycomed has granted,Sepracor, Inc. ... marketing and,commercialisation rights for Ciclesonide in the ... a novel principle of action. It,is the ... for the,treatment of asthma and in the ...
... Joseph F. Finn, Jr.,CPA, the Assignee for the Benefit ... of the Company,s fixed assets for in,excess of $300,000 ... to,the high volume of requests for due diligence materials ... the Company has,created an online datasite that allows access ...
Cached Biology Technology:Rice wins innovation award for international program 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... per eight hundred births, Down syndrome - or trisomy ... intellectual disability. It results from a chromosomal abnormality where ... chromosome 21 (1% of the human genome). A study ... Department of Genetic Medicine and Development at the University ... Nature , shed light on how the extra chromosome ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... The common fruit fly circling your week-old peach has ... the insect,s eggshell formation. The paradoxical finding gives ... eggshell layer forms as it points to a likely ... biologist in the Medical College of Georgia Schools of ...
... plain with the odd hydrothermal vent, the seafloor appears ... paper being published May 29 in Nature. A ... mid-ocean ridge spreading system, representing potentially the largest surface ... geomicrobiologist Katrina Edwards, the studys corresponding author. While ...
... WEST LAFAYETTE, Ind. - Throughout the overlooked depths of ... important animal is rapidly disappearing. Until recently, the ... was a major food source for commercially important species ... salmon, trout and walleye rely. Scientists are employing ...
Cached Biology News:Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3'Barren' seafloor teeming with microbial life 2'Barren' seafloor teeming with microbial life 3A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... both 0.2 and 2.0 mL samples for freezing point determinations. Includes built-in ... reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: